Fresenius SE & Co. (OTCMKTS:FSNUY) Shares Shorted: Short Interest Up 86.7% in September

Fresenius SE & Co. (OTCMKTS:FSNUY) was the target of a large growth in short interest during the month of September. As of September 15th, there was short interest totaling 59,859 shares, a growth of 86.7% from the August 31st total of 32,056 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average trading volume of 159,917 shares, the short-interest ratio is presently 0.4 days.

Wall Street Analysts Forecast Growth

Several research firms recently commented on FSNUY. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Fresenius SE & Co. in a research report on Thursday, August 6th. Morgan Stanley reiterated an “overweight” rating on shares of Fresenius SE & Co. in a report on Tuesday, July 21st. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Fresenius SE & Co. currently has an average rating of “Buy”.

Fresenius SE & Co. Trading Down 7.0%

Shares of Fresenius SE & Co. stock traded down $0.93 during midday trading on Tuesday, reaching $12.42. The company had a trading volume of 7,321 shares, compared to its average volume of 145,590. The stock has a fifty day moving average price of $13.18 and a 200 day moving average price of $12.42. Fresenius SE & Co. has a fifty-two week low of $10.33 and a fifty-two week high of $33.93. The firm has a market cap of $27.98 billion, a PE ratio of 15.72 and a beta of 0.62. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.28 and a quick ratio of 0.97.

Fresenius SE & Co. (OTCMKTS:FSNUY) last released its earnings results on Wednesday, August 5th. The company reported $0.24 earnings per share for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). Fresenius SE & Co. had a net margin of 6.67% and a return on equity of 10.25%. The firm had revenue of $6.91 billion for the quarter, compared to analyst estimates of $6.65 billion. On average, equities analysts anticipate that Fresenius SE & Co. will post 1.08 earnings per share for the current year.

Fresenius SE & Co. Company Profile

Fresenius SE & Co KGaA is a German healthcare company headquartered in Bad Homburg, Germany. The group develops and provides products and services for hospitals, outpatient care providers and patients, with operations focused primarily on healthcare products and hospital services.

Its Fresenius Kabi business supplies medicines and technologies used in infusion therapy, clinical nutrition and transfusion medicine. Its portfolio includes intravenous drugs, generic medicines, biosimilars, infusion systems, medical devices and products for parenteral and enteral nutrition.

Fresenius also operates hospitals through Helios, which manages acute-care and rehabilitation facilities in Germany and hospitals and other healthcare services in Spain through the Quirónsalud network.